Adipose tissue secretes a number of biologically active adipokinesone of them is Adiponectin. However there is no data about the secretionof adiponectin during hepatitis C infection, some studies revealed that inchronic HCV patient's hypoadiponectinemia is significantly associatedwith the development of liver steatosis. Adiponectin may be an attractivetherapy for fatty liver disease.The aim of this study is to define a potential role of adiponectin inpatients with chronic hepatitis C virus infection in Egypt and toinvestigate its role in HCV-related steatosis. The present study was conducted on forty-fore patients sufferingfrom chronic hepatitis C and sixteen healthy volunteers served ascontrols. The subjects selected from the National Research Institute forTropical Medicine and Liver Disease. The significant finding of this study is that the chronic HCV patientshave reduced circulating adiponectin levels than healthy controls (12.7±8.2 for HCV vs. 19.5 ± 11.6 for control, P = 0.04). The results of thepresent study suggest that there is no significant correlation seen betweenadiponectin and steatosis as well as the grades of steatosis as meanadiponectin level is 9.00 ± 7.45 in steatosis < 30% while it is 14.50 ± 2.12in steatosis > 30% ( P = 0.29 ). In conclusion, this study demonstrates that hypoadiponectinaemia inHCV-infected patients did not correlate with hepatic steatosis.